Skip to main content
TipRanks
Go Ultimate75% OFF

Medifast (0K05) AI Stock Analysis

2 Followers
GB:0K05

Medifast

(LSE:0K05)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-free balance sheetThe debt-free balance sheet and substantial cash reserve provide financial flexibility while Medifast restructures its cost base and invests in growth initiatives. This liquidity reduces near-term financing pressure and gives management capacity to support the Trilogy transition despite current operating losses.
Negative Factors
Sharp revenue contractionThe prolonged revenue decline shows that Medifast has not yet stabilized demand after the business contracted substantially. A smaller sales base reduces operating leverage, limits reinvestment capacity, and makes a durable return to profitability dependent on reversing the underlying customer and coach trends.

Medifast (0K05) vs. iShares MSCI United Kingdom ETF (EWC)

-20%-10%0%10%20%30%GB:0K05+14.50%EWC+16.25%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$136.43M
Dividend Yield
―
Average Volume (3M)
207
Price to Earnings (P/E)
-3.3
Beta (1Y)
0.54
Revenue Growth
-30.28%
EPS Growth
-16409.29%
Country
UK
Employees
380
Sector
Consumer Cyclical
Sector Strength
61
Industry
Personal Products & Services

Medifast Business Overview & Revenue Model

Company Description

Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness. These products are distributed across the United States and the...

Medifast Earnings Call Summary

Earnings Call Date:Oct 26, 2026(Q3-2026)|% Change Since:2.27%|Next Earnings Date:Feb 23, 2027
Earnings Call SentimentNeutral

The call was cautiously positive. Management highlighted successful execution of the Trilogy 3.0 launch, improving coach productivity, strong product adoption, a debt-free balance sheet, cost realignment, and a stated path to fourth-quarter profitability. However, these positives were offset by a 19.4% revenue decline, a substantial reduction in active earning coaches, continued GLP-1-related pressure on the traditional weight loss category, and significantly larger GAAP operating and net losses. The outlook is constructive but remains dependent on improving coach growth while sustaining productivity gains.

Positive Updates

Revenue In Line With Guidance and Stabilizing
Third-quarter revenue was $72 million, in line with guidance and continuing the trend of revenue stabilizing around $75 million for the fourth consecutive quarter.

Negative Updates

Revenue Declined Year Over Year
Third-quarter revenue of $72 million decreased 19.4% versus the year-earlier period, primarily due to a decrease in the number of active earning coaches.

Company Guidance

Medifast expects fourth quarter revenue to range from $55 million to $75 million and income per share for the quarter to range from $0.00 to $0.25; while it expects to continue to see the active earning coach count to decline through the end of the year, it expects to see continued coach productivity growth during the quarter, up both year over year and sequentially. For the full year 2026, it expects revenue to range from $280 million to $300 million and loss per share between $1.80 and $2.05, and on a non GAAP basis, loss per share between $0.45 and $0.70. It expects fourth quarter adjusted EBITDA, excluding interest income, to range from $2 million to $6 million, and for the full year 2026, adjusted EBITDA, excluding interest income, to range from $10 million to $14 million; the company is targeting profitability in the fourth quarter of 2026.

Medifast Risk Analysis

Medifast disclosed 25 risk factors in its most recent earnings report. Medifast reported the most risks in the "Ability to Sell" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Ability to Sell - Risks related to the company’s ability to sell goods and services

Latest Risks Added

0 New Risks

Medifast Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

GB:0K05 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$18.38B12.79-2.54%3.03%1.52%-15.83%
WWWW54Neutral$89.59M-3.02-9.92%―-11.74%-102.54%
MRMMRM44Neutral$2.16M-0.55-68.38%―――

* Consumer Cyclical Sector Average

Performance Comparison

-50%0%50%GB:0K05MRMWWDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0K05 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0K05Medifast12.161.4413.41%
MRMMedirom Healthcare Technologies, Inc.0.26-1.75-86.87%
WWWW International, Inc.8.63-12.50-59.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.